Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax: 2022-2023

Historic Long-Term Deferred Tax for Syndax Pharmaceuticals (SNDX) over the last 2 years, with Dec 2023 value amounting to $79.6 million.

  • Syndax Pharmaceuticals' Long-Term Deferred Tax rose 62.78% to $79.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $79.6 million, marking a year-over-year increase of 62.78%. This contributed to the annual value of $79.6 million for FY2023, which is 62.78% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Long-Term Deferred Tax of $79.6 million as of FY2023, which was up 62.78% from $48.9 million recorded in FY2022.
  • Syndax Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $79.6 million for FY2023, and its period low was $48.9 million during FY2022.
  • In the last 2 years, Syndax Pharmaceuticals' Long-Term Deferred Tax had a median value of $64.2 million in 2022 and averaged $64.2 million.
  • Data for Syndax Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY skyrocketed of 62.78% (in 2023) over the last 5 years.
  • Yearly analysis of 2 years shows Syndax Pharmaceuticals' Long-Term Deferred Tax stood at $48.9 million in 2022, then surged by 62.78% to $79.6 million in 2023.